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Abstract
Background: With a growing number of genetic tests becoming available to the health and
consumer markets, genetic health care providers in Canada are faced with the challenge of
developing robust decision rules or guidelines to allocate a finite number of public resources. The
objective of this study was to gain Canadian genetic health providers' perspectives on factors and
criteria that influence and shape resource allocation decisions for publically funded predictive
genetic testing in Canada.
Methods: The authors conducted semi-structured interviews with 16 senior lab directors and
clinicians at publically funded Canadian predictive genetic testing facilities. Participants were drawn
from British Columbia, Alberta, Manitoba, Ontario, Quebec and Nova Scotia. Given the community
sampled was identified as being relatively small and challenging to access, purposive sampling
coupled with snowball sampling methodologies were utilized.
Results: Surveyed lab directors and clinicians indicated that predictive genetic tests were funded
provincially by one of two predominant funding models, but they themselves played a significant
role in how these funds were allocated for specific tests and services. They also rated and identified
several factors that influenced allocation decisions and patients' decisions regarding testing. Lastly,
participants provided recommendations regarding changes to existing allocation models and
showed support for a national evaluation process for predictive testing.
Conclusion: Our findings suggest that largely local and relatively ad hoc decision making processes
are being made in relation to resource allocations for predictive genetic tests and that a more
coordinated and, potentially, national approach to allocation decisions in this context may be
appropriate.
Background
Canada has invested significant funding for genetic
research, yielding new technologies and, in turn,
increased patient demand [1]. As genetic technologies
continue to be introduced into mainstream health care,
assessment raises difficult issues for health care providers
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and policymakers [2]. Broadly speaking, these parties are
faced with allocating resources for an ever-expanding list
of new genetic health technologies in the context of the
existing and future pressures to the health care system.
Assessment for genetic technologies raises questions with
regard to legal and ethical duties of care owed by health
care providers involved in the provision of genetic services
[3-5]. It also faces the practical challenges of generating
and incorporating robust evidence into health care
resource allocations [6], finding the appropriate balance
between quantitative and qualitative information [7], and
setting uniform evaluation standards across highly varia-
ble testing and health outcomes [6]. A variety of new
assessment models have developed alongside emerging
genetic technologies [8-10]. However, with only prelimi-
nary policy development for resource allocation for such
technologies [11-13], Canadian technology assessment
has evolved as a predominantly informal, ad hoc process.
Health providers play a key role in decisions about the uti-
lization of genetic technologies and, as such, their per-
spective on genetic medicine is of value [14,15]. For the
purposes of this paper genetic medicine has been defined
as "the study of genetic mechanisms including the genetic
basis for human diseases, and the development of geneti-
cally based tests and therapies" [16].
In 2007, the authors conducted a study which consisted of
a series of semi-structured interviews with senior lab direc-
tors and clinicians at publicly funded Canadian predictive
genetic testing facilities. These interviews were designed to
provide key information regarding the allocation of
resources for predictive genetic testing and associated eth-
ical, legal and social issues. More specifically, they
explored existing provincial funding structures, criteria
and factors that influence resource allocation decisions,
relationships between primary health providers and gov-
ernment representatives, the role the media plays in influ-
encing patients' requests for genetic tests, and the
strengths and weaknesses of the current regulatory frame-
work within which these facilities operate. Policy recom-
mendations regarding changes to resource allocation
models and the viability of a national evaluation process
for predictive genetic tests were also examined. Informa-
tion obtained from these interviews has been used to
inform ongoing research investigating resource allocation
of emerging genomic technologies, the end goal of which
is to formulate a list of funding policy recommendations
to assist in resource allocation decisions.
The facilities and individuals providing predictive genetic
testing – or tests that help determine an individual's pre-
disposition to a particular health condition or disease – is
a relatively small community in Canada, and those inter-
viewed were identified by their community as leaders in
this context. The interviews specifically focused on predic-
tive genetic testing for adult onset hereditary diseases,
such as breast and colon cancer, and Huntington's dis-
ease.
Methods
This paper presents the results of a study exploring senior
lab directors' and clinicians' perspectives on resource allo-
cation for predictive genetic testing in Canada and associ-
ated ethical, legal and social issues. As the community
sampled was identified as being relatively small and chal-
lenging to access, purposive sampling coupled with snow-
ball sampling methodologies were utilized [17,18].
A preliminary list of potential interview participants was
created through consultation with project collaborators
and senior lab directors, with reference to the Canadian
College of Medical Geneticists membership directory. A
total of 45 individuals were invited by email to gauge
interest in completing the interviews, and were subse-
quently contacted by telephone. Of the original sample of
45, the authors were able to speak with 31 potential par-
ticipants. During the initial discussions with these indi-
viduals, the authors asked them to identify the best
member within their local genetic testing community to
interview. Eleven individuals referred the authors to other
genetic community members – all of whom were on the
original contact list – three declined to participate, and
scheduling conflicts prevented the participation of one,
resulting in a final sample of 16. Between January-March
2007, semi-structured interviews were conducted with
individuals from the final sample either by telephone
(14) or by email (2) according to the respondent's prefer-
ences, with the average telephone interview lasting
approximately 40 minutes. Participants were drawn from
British Columbia, Alberta, Manitoba, Ontario, Quebec,
and Nova Scotia, and the final sample was composed of
eight lab directors and eight clinicians.
The semi-structured interview instrument was developed
in consultation with project collaborators and senior cli-
nicians. In total 13 questions were included, and data was
collected through a series of both open and closed ended
questions. All participants received a copy of the survey
instrument in advance of their scheduled telephone inter-
view and all interviews were conducted by the same indi-
viduals. They were tape-recorded and open ended
responses were transcribed at the time the interviews were
conducted. For those that participated via telephone, con-
sent to participate was obtained before the survey com-
menced, and was recorded on tape. For those participants
that completed the survey via email, consent to participate
was explained to be implicit in their completion of the
survey. Given the small sample size, results are descriptive
and have no transferrable statistical significance. Open
ended questions were transcribed and general themes
were simply identified. For closed ended questions,BMC Medical Ethics 2009, 10:6 http://www.biomedcentral.com/1472-6939/10/6
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responses were simply counted on a question by question
basis and compared to the total sum of responses given
for each corresponding question. Participants were also
given the opportunity to discuss any additional topics or
issues they wished to raise.
The University of Alberta Art, Science and Law Research
Ethics Board approved the research protocol. Responses
were de-identified by assigning provincial locations and a
number to each participant. Information from the study
that could render individuals identifiable in any way has
not been included in published results.
Results
Policy at National, Provincial and Laboratory Levels
Funding for genetic testing varies widely across Canada
[1]. The Canadian health care system is essentially com-
prised of a grouping of provincial systems and health care
delivery is considered a provincial matter with each prov-
ince allocating funds for services slightly differently. These
structural variations help to create different approaches to
the funding of genetic tests. Surveyed lab directors and cli-
nicians were asked to explain how predictive genetic tests
were funded at their facility. Their responses identified
two predominant funding models. In provinces such as
Quebec, Nova Scotia, Alberta and Ontario, participants
explained that funding is allocated to hospital and
regional budgets. The hospital or region in turn makes
decisions about the overall yearly budget for their respec-
tive genetic laboratories. For example, one participant
from Ontario explained:
What happens in Ontario, the genetic testing comes
out of the hospital budget, the hospital gives X
number of dollars to genetic testing. In other prov-
inces the funding goes directly for genetic testing. In
some cases, there is a mix. For BRCA1 there is targeted
[funding] for a few centres. For the majority of the
other 200 DNA tests it comes through the global hos-
pital budget.
In provinces such as British Columbia and Manitoba,
funding is allocated directly to the genetic laboratory
under the province's respective Ministry of Health. The
hospital does not intervene in resource allocation deci-
sions. A participant from one of these provinces
explained:
Predictive genetic tests are funded through the Molec-
ular Diagnostic Laboratory budget which in turn is
provided through the local regional health authority
budget.
In all provinces surveyed, the lab directors or head clini-
cians generally played a significant role in allocating the
funds they received to specific tests and services, influenc-
ing day-to-day utilization decisions.
It was also found that participants were largely making
such everyday allocation decisions without consultation
with government representatives. Respondents were que-
ried on the nature of their relationship with national and
provincial government representatives. Participants were
asked: "Who in the federal and/or provincial government
has a role in the implementation of predictive genetic tests
and resource allocation at your facility? Do you work with
them?" While, a third of respondents (5/16) were able to
identify a process for contacting the provincial govern-
ment, two thirds of participants (11/16) indicated, in fact,
that there was no one in the federal or provincial govern-
ment that they could pinpoint as having a role. For exam-
ple, one person stated "the contact person changes all the
time, right now no one actually knows who the contact
person is." Another explained:
No one in the provincial government, as far as I know,
has a role in implementing predictive genetic tests.
We, geneticists, have written proposals to implement
genetic tests either in-house or through an out-of-cen-
tre laboratory. I do know that only a handful of pro-
posals are brought forward to the attention of the
provincial Minister of Health's office. Which propos-
als that are moved forward is decided by senior
regional health authority officials and which ones are
ultimately funded is decided by governmental offi-
cials.
These responses support a picture of an allocation process
that is largely regional and localized to the health care
community.
Respondents from across Canada also revealed that allo-
cation decisions related to the distribution of funds for
predictive genetic tests at the laboratory level were being
influenced by a variety of factors. Underfunding for
genetic tests was a recurrent theme in the discussion.
When asked "are there any tests that have received prema-
ture funding," only one response indicated such incidents
(1/16). In contrast, when asked, "are there tests that are
not currently funded that your facility would like to pro-
vide" almost all respondents (15/16) answered in the
affirmative. Participants were also asked to rate on a scale
of 1–5, with 5 being very important and 1 not important,
a list of potential factors influencing resource allocation
decisions for predictive genetic testing at their facility
These included: cost effectiveness, length of wait times,
access to the appropriate equipment, access to new tech-
nologies, evidential basis, availability of preventative
strategies, ethical/legal consideration, and media cover-
age. Participant responses varied, but for each of the fac-BMC Medical Ethics 2009, 10:6 http://www.biomedcentral.com/1472-6939/10/6
Page 4 of 6
(page number not for citation purposes)
tors listed, over half of the participants gave a rating of 3
or higher, with evidential basis and cost effectiveness con-
sistently receiving the highest ratings. Such ratings suggest
that all the above factors influence resource allocation
decisions for predictive genetic testing in Canada at the
laboratory level.
A number of participants then offered recommendations
for changes to resource allocations specifically related to
the mechanisms used to fund predictive genetic tests.
When asked: "How do you think predictive genetic tests
should be funded?" participants expressed a range of
views. Some participants (5/16) indicated a preference for
funding on a per test basis, e.g., "We need to be funded for
each test that we are doing." A small minority (2/16) iden-
tified a preference for specific set of funds allocated to
each type of genetic test, e.g., "It would be better to have
funds specifically allocated for [predictive genetic testing]
so if there is a need for further funding the lab would have
the ability to justify itself."
Others noted (5/16) that the current mechanism through
which funds were being allocated was satisfactory, in par-
ticular those that were funded under a global budget. One
of these participants supported the evaluation process at a
hospital-based laboratory, whereby funding for genetic
testing was allocated after an evidence-based committee
review, explaining:
We have a committee that decides if it is a novel test.
The person that is requesting this goes in front of a
committee that decides if it is scientifically sound, and
how it is going to impact on our hospital... This [is]
fairly straightforward.
The remainder of those interviewed (4/16) explained their
funding systems but did not comment on their level of
satisfaction.
The study sought to discover whether there was support
for further policy development for technology assessment
for genomic health technologies, initiated at the national
level. When asked: "Do you think a national evaluation
process for all predictive testing would be useful?" three
quarters of participants (12/16) responded in the affirma-
tive, e.g., "Canadian national guidelines would be a good
place to start" and " [it would be] useful to have national
standards on what is paid for and for those to be informed
by expertise." Of those interviewed, the difficulty of coor-
dinating or implementing a national evaluation process
was raised (6/16), including by four of the participants
who were supportive of new standards, e.g.:
We live in a country where healthcare is the provincial
jurisdiction. Whatever we say national is unlikely to
impact resources. But the federal government could
put money into the Canadian College of Medical
Genetics to push standardization, to ensure tests are
performed in an excellent fashion, standards for
genetic counseling – that would be great.
These participants also emphasized the need for sensitiv-
ity to the local and provincial nature of health care, cau-
tioning, e.g., " [there are] very big regional differences and
pressures per region."
Legal, Ethical and Social Issues
The study also focused on the relationship between
resource allocation and the legal and ethical duties of care
owed by health care providers involved in the provision of
genetic services in the context of resource allocation poli-
cies [4,6,19]. Respondents were asked, "Assuming patient
consent, who makes the decision about whether a predic-
tive genetic test will be done?" Four options were pro-
vided: the primary care physician, the specialist, the
genetic counselor or the laboratory. The majority of par-
ticipants (11/16) indicated that more than one profes-
sional is involved in this process. Many respondents
suggested that determining the professional responsible
for making a decision on testing is dependant on the type
of test. e.g., "There are certain tests where we would allow
the primary care physician to make the decision, and there
are certain tests where we need a genetic counselor to
make the decision." One respondent deferred to policies
rather than individual decision-making, suggesting "I am
not sure if there is much of a decision because there are
protocols in place so if they meet the protocols they get
the test." This variability raises questions about the ethical
responsibilities of each professional, as well as questions
with regard to clarity regarding who has ultimate legal
responsibility in relation to the decision making process.
Respondents were also questioned on a scenario that
poses legal and ethical challenges for health care provid-
ers. They were asked "When should a patient's desire to
have a specific test overrule the clinical indication for the
test?" and offered three options – always, sometimes,
never. Three quarters of respondents (12/16) replied that
this decision should be made sometimes, depending on
other social factors or the strength of the request. Gener-
ally, participant responses focused on the standard of care
that they should be providing as health care professionals,
e.g., "there are times when people are so stressed out that
that might be an indication on its own." While those sur-
veyed offered little insight into the nature of the legal obli-
gations they owed in this role, the responses seem to
represent a thoughtful balancing of an evidence based
approach and a consideration of ethical obligations.
The study also investigated genetics health care providers'
perceptions of social factors influencing patient decisions
about predictive genetic testing. Respondents were askedBMC Medical Ethics 2009, 10:6 http://www.biomedcentral.com/1472-6939/10/6
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to rate the influence of patients' concern about genetic dis-
crimination, impact on family members, ability to obtain
insurance, and additional costs associated with a positive
result, on decisions regarding testing [20-22]. Providers
offered a range of perceptions on patients' influences. In
particular, genetic discrimination was viewed as both, e.g.,
"A high concern for most patients" and something that "
[does not come] up all too often, in our health care sys-
tem." Overall, half of the participants (8/16) rated the
influence of patients' concern about genetic discrimina-
tion, as a 3 or higher, on a scale of 1 to 5, with 5 being very
important and 1 not important. Interestingly, a couple
respondents (2/16) also commented that factors such as
genetic discrimination and the ability to obtain insurance
are not normally influential until raised by health provid-
ers: "That's often an issue, again often one that we raise
that they may not have thought about." In other words,
providers expressed that patients were often unaware of
the potential for genetic discrimination or difficulty
obtaining insurance before their genetic health provider
raised these issues.
Finally, the study queried genetic health care providers'
perceptions of the influence of the media. When asked to
rate the influence of "media portrayals of genetics on
patient requests for genetic tests," on a scale, with 5 being
very influential and 1 not influential, a majority of
respondents (11/16) affirmed that media portrayals were
either rated as a 4 or a 5. These findings emphasize the
role of the media as an information conduit and a public
education tool that assists in the introduction of new
genetic technologies; one participant noted " [the media]
have done a better job than the medical community."
Respondents were also cautious about the tendency for
information on genetic issues to become disproportion-
ately emphasized, e.g., "The press is great for advocacy,
not so good on issues requiring a perspective. That said,
the media does keep us on our toes and does have a role."
These findings confirm what other research has found
regarding the media in the context of genetic technologies
[23-25], including an awareness of genomics hype
through media attention, and underscore the importance
of accounting for social pressures on resource allocation
structures.
Discussion
Internationally, the reviews of appropriate standards for
robust decision making processes and frameworks for the
delivery of new health technologies, including genetic
testing, are emerging. For example, in 2006 the New Zea-
land government examined the role of evidenced based
medicine in health boards' decision making processes,
considering the factors that influenced decisions by health
boards; national and regional decision making processes;
and views on evidence based medicine from the clini-
cian's perspective [26]. This study was motivated by the
need to develop further insight into Canadian resource
allocation issues in the context of predictive genetic test-
ing. The value of understanding the provider perspective
and the impact it might have on allocation policy is key.
Genetic professionals are a vital part of the allocation
process, making daily clinical decisions regarding utiliza-
tion and playing a unique role in policy development.
Despite some controversy about the clinical utility of
genetic testing [27,28] and the robustness of the technol-
ogy assessment surrounding their implementation [9,28],
the perception from Canadian clinicians is that genetic
tests are not receiving premature public funding and that,
in fact, more tests should receive funding. From the health
care professional perspective, the pressure will be for more
funds and increased testing. Legal and ethical factors may
also drive utilization. These pressures would likely be
most effectively balanced by the development of inde-
pendent, evidence based allocation policies and clinical
practice guidelines.
This study has a number of limitations. In addition to a
small sample size, and therefore limited generalizablity of
results, telephone and email surveys have the potential to
yield different results as they are each distinct modes of
data collection. Despite these limitations the findings pro-
vide baseline data on key players' perspectives on factors
and criteria that influence and shape the allocation of
resources for publically funded predictive genetic testing
in Canada.
Conclusion
As new genetic tests continue to become available to the
health care system, the importance of an effective decision
making process for distributing the limited quantity of
available health care funding will remain at the forefront.
While it is important to recognize the value of the regional
and provincial decision making that is currently being
undertaken with regard to allocating funds for new tech-
nologies in Canada, the role of national policies and guid-
ance should also be considered. In the United Kingdom,
the evaluation of and decision to allocate resources to new
genetic tests is completed under the umbrella of the UK
Genetic Testing Network (UKGTN) [29], a national frame-
work for the delivery of genetic tests. Under this system,
when a laboratory or health care client wants a new
genetic test to be adopted by the UKGTN, a "gene dossier"
must be submitted which includes information on the
"disease prevalence, test characteristics, utility and validity
of the test" and which is reviewed by the Steering Com-
mittee that prioritises the requests [29,30].
This unified approach stands in contrast to the largely
local and relatively ad hoc decision making processes
described by genetic providers interviewed in this study.
As discussed above, few of those interviewed – despiteBMC Medical Ethics 2009, 10:6 http://www.biomedcentral.com/1472-6939/10/6
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being leaders within the clinical genetics community –
could identify any relevant provincial or federal govern-
ment contact. In addition, while a broad range of often
conflicting factors impact allocation decisions, including
for example, media coverage, patient demands, and legal
and ethical issues, there is no single strategy for prioritiz-
ing needs or allocating funds. It is not surprising, then,
that there was general agreement concerning the value of
national policies. Indeed, our data lends support to the
development of a more coordinated and, potentially,
national approach to allocation decisions in this context.
That is not to say that participants favored overriding cur-
rent processes and the multiple variants at play in stake-
holder decisions. Participants acknowledged the
complexity of coordinating a national review in Canada
given the provincial jurisdiction of health care funding.
With this in mind, however, a national forum would pro-
vide the opportunity to support these decision making
processes while clarifying prioritization criteria, encourag-
ing provincial interrelationships, and promoting stand-
ardization.
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